MindMaze Therapeutics Holding SA has officially emerged from the merger between Relief Therapeutics Holding SA and NeuroX Group SA, a significant development in the field of digital treatments for neurological diseases. Announced on December 15, 2025, this newly formed entity aims to revolutionize neurological care by integrating various therapeutic approaches and advanced technologies.
The completion of this business combination follows the signing of a definitive agreement in October 2025 and subsequent shareholder approval during an extraordinary general meeting in November. The merger creates a comprehensive platform that combines precision digital neurotherapeutics, pharmacological treatments, and cutting-edge devices powered by artificial intelligence. This innovative ecosystem is designed to enhance patient outcomes significantly.
Olaf Blanke, a member of the Board of Directors and Professor of Neuroscience at the Swiss Federal Institute of Technology, emphasized the urgency of addressing neurological diseases. “Neurological diseases are one of the leading causes of disability globally,” he stated. He noted that with aging populations, approximately 1 in 6 people is expected to develop a neurological condition, underscoring the need for effective and scalable solutions.
Despite the high demand for neuro-rehabilitation, traditional healthcare systems often fall short in providing adequate therapy. MindMaze Therapeutics aims to bridge this gap by offering clinically validated neurotherapeutics that support patients throughout their recovery journey—from hospital settings to rehabilitation centers and home environments.
Walid Hanna, Chairman of the Board of Directors of the new company, expressed optimism about the merger’s potential. “Today begins a new chapter for MindMaze Therapeutics,” he remarked. “Our mission is to transform neurological care and address critical gaps in motor and cognitive restoration for neurological conditions.” He highlighted that the combined capabilities of the two companies will enhance their growth strategy and expand development opportunities.
The acquisition of NeuroX was executed through a share exchange, where all outstanding shares of NeuroX were converted into 140,000,000 newly issued ordinary shares of MindMaze. These shares will commence trading on the SIX Swiss Exchange under the updated ticker symbol MMTX. Following the merger, the total number of outstanding shares stands at 152,602,044, excluding treasury shares.
About MindMaze Therapeutics
MindMaze Therapeutics is a Swiss-based company formed in December 2025 through the merger of Relief Therapeutics and NeuroX. The company focuses on developing and commercializing innovative digital treatments for neurological diseases. Utilizing an advanced brain technology platform that integrates software, sensors, and telehealth, its solutions are deployed in various clinical and home settings worldwide.
The company’s clinically validated neurotherapeutics have shown promising medical and economic outcomes in treating conditions such as stroke, Parkinson’s disease, and age-related issues. MindMaze is committed to expanding its research and development pipeline into additional neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.
Additionally, MindMaze Therapeutics is responsible for managing Relief’s existing portfolio of clinical and commercial biopharmaceutical assets that target rare dermatological, metabolic, and respiratory diseases. The company is listed on the SIX Swiss Exchange under the ticker MMTX and is also quoted in the United States on OTCQB under RLFTF and RLFTY.
For more information about their innovative therapies and research, visit www.mindmazetherapeutics.com.
Contact:
MindMaze Therapeutics Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
This announcement contains forward-looking statements, which may involve risks and uncertainties that could cause actual results to differ materially from those anticipated. MindMaze Therapeutics undertakes no obligation to update any forward-looking statements as new information becomes available.
